Trinity Biotech plc (TRIB)
TRIB trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/888721/000155485526000848/0001554855-26-000848-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TRIB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | Ireland |
| IPO year | 1992 |
| SEC CIK | 0000888721 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | Ireland |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $43.8M |
| Net income | -$37.4M |
| Operating income | -$15.8M |
| Net margin | -85.4% |
| Operating margin | -36.1% |
| Revenue growth | -28.9% |
| Cash | $5.1M |
| Total assets | $105.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-04-30 |
| Cash and burn | $5.1M cash; operating cash flow -$1.5M a quarter. | Report 2025-12-31 |
| Shares outstanding | 623,678 (2025-12-31); 17,959,674 a year earlier; 7,621,514 three years earlier. 3y figure adjusted for splits (1-for-5 overall); the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | 2; latest 1-for-30 on 2026-07-24 | Source 2026-07-24 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-06-12 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grant Thornton, Dublin, Ireland | PCAOB Form AP 2026-06-03 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $43.8M | -$37.4M | -$5.9M | $5.1M | $210K | $43.8M | 20-F 2026-04-30 |
| FY 2024 2024-12-31 | $61.6M | -$31.8M | -$4.2M | $5.2M | $210K | $61.6M | 20-F 2025-05-16 |
| FY 2023 2023-12-31 | $56.8M | -$24.0M | -$11.6M | $3.7M | $210K | $56.8M | 20-F 2025-05-16 |
| FY 2022 2022-12-31 | $62.5M | -$41.0M | -$921K | $6.6M | $210K | $62.5M | 20-F 2025-05-16 |
| FY 2021 2021-12-31 | $81.1M | $875K | $13.2M | $25.9M | $83.3M | $81.1M | 20-F 2024-04-30 |
| FY 2020 2020-12-31 | $102.0M | -$6.4M | $23.8M | $27.3M | $1.0M | $102.0M | 20-F 2023-05-16 |
| FY 2019 2019-12-31 | $90.4M | -$28.9M | $5.4M | $15.2M | $1.0M | $90.4M | 20-F 2022-05-02 |
| FY 2018 2018-12-31 | $97.0M | -$22.1M | $7.2M | $30.3M | $99.9M | $97.0M | 20-F 2021-04-30 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2026-08-28 |
| Latest annual report | 20-F | 2026-04-30 |
| Latest quarterly / interim | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 502 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +7.0% |
| 1 month | -3.2% |
| 3 months | -48.6% |
| Year to date | -74.3% |
| 1 year | -76.1% |
| From 52-week high | -84.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CDIO | Cardio Diagnostics Holdings Inc. | $1.79 | -7.26% | $5.3M |
| BMRA | Biomerica Inc. | $1.32 | -2.94% | $6.1M |
| VNRX | VolitionRX Limited | $0.1998 | -13.13% | $7.2M |
| QCLS | Q/C Technologies Inc. | $0.3210 | +4.80% | $2.6M |
| VRAX | Virax Biolabs Group Limited | $0.4480 | -26.87% | $603K |
| IMDX | Insight Molecular Diagnostics Inc. | $1.86 | -13.08% | $60.9M |
| ICCC | ImmuCell Corporation | $11.42 | +6.23% | $103.8M |
| TKNO | Alpha Teknova Inc. | $7.77 | -5.36% | $488.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier